United Therapeutics (NASDAQ:UTHR) Director Louis Sullivan Sells 5,950 Shares

United Therapeutics Corporation (NASDAQ:UTHR) Director Louis Sullivan sold 5,950 shares of the stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $512.13, for a total value of $3,047,173.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

United Therapeutics Stock Performance

NASDAQ UTHR traded down $3.35 during mid-day trading on Tuesday, reaching $510.44. 382,700 shares of the stock were exchanged, compared to its average volume of 581,627. The stock has a market capitalization of $21.98 billion, a PE ratio of 19.34, a PEG ratio of 5.13 and a beta of 0.86. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $519.99. The business’s fifty day simple moving average is $465.10 and its 200 day simple moving average is $382.72.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same period in the prior year, the firm posted $6.39 EPS. The company’s revenue was up 6.8% on a year-over-year basis. On average, analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. AIA Group Ltd bought a new stake in shares of United Therapeutics in the 3rd quarter valued at approximately $545,000. Allworth Financial LP grew its position in United Therapeutics by 26.1% in the third quarter. Allworth Financial LP now owns 449 shares of the biotechnology company’s stock worth $188,000 after acquiring an additional 93 shares in the last quarter. Cambria Investment Management L.P. increased its stake in shares of United Therapeutics by 20.9% during the 3rd quarter. Cambria Investment Management L.P. now owns 2,657 shares of the biotechnology company’s stock worth $1,114,000 after purchasing an additional 460 shares during the last quarter. CIBC Private Wealth Group LLC increased its stake in shares of United Therapeutics by 66.2% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 713 shares of the biotechnology company’s stock worth $299,000 after purchasing an additional 284 shares during the last quarter. Finally, CIBC Bancorp USA Inc. bought a new position in shares of United Therapeutics during the 3rd quarter valued at $644,000. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on UTHR shares. Wells Fargo & Company boosted their price objective on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Morgan Stanley set a $447.00 target price on United Therapeutics in a research report on Wednesday, October 29th. HC Wainwright upped their price target on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday. Finally, Royal Bank Of Canada boosted their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.